The Patient's Eye — I Am the One Who Takes This Drug

The patient is the ultimate recipient of any promotional material. Yet most materials are designed with the physician in mind, and review proceeds on the same assumption. The problem is that the distortions in those materials travel through the prescription to the patient's body. The patient does not know what a contraindication is. They cannot assess whether a side-effect frequency qualifies as "rare." They read "consistent efficacy across a broad range of patients" and start taking the drug. Without this perspective, it is not possible to properly evaluate whether safety information has been skewed.

So What / So Why — The Core of This Perspective

So what (what does this perspective look at)  The patient's eye means receiving the words in a material as a person without medical training. Reviewers typically evaluate materials on the assumption that a physician reading them will supply the necessary context. But at the end of that evaluation stands a patient who received an explanation from that physician. Physicians sometimes relay the material's exact language to patients. For patient-facing brochures and medication counseling aids, patients read the material directly. A single sentence in that document lands in the hands of someone who cannot independently assess whether the prescription is appropriate.

So why (why this perspective belongs in the review process)  Efficacy information travels easily; safety information does not. This is a structural feature of human information processing, and it affects both the people who create materials and the people who receive them. Patients approach materials hoping the drug will work. Their eyes slide past contraindications and adverse-effect descriptions. The colors used in a patient-facing piece, the size of a diagram, which words are bolded, the order of explanation — all of these can shift the apparent weight of information, intentionally or not. A reviewer who cannot imagine this reception from the inside will miss the cues built into a design.

Patients bear the risk. A physician decides to prescribe, a reviewer allows the material through, and at the end of that chain is the patient who swallows the pill. Bringing that fact into the review room is what this perspective is for.

What the Perspective Covers — What / Where / Why / How

What (what to look at in materials through the patient's eye)

• How much space, color, and diagramming is devoted to efficacy, and how much to safety
• Whether contraindication and precautionary-use descriptions are specific enough for a patient to recognize that the warning applies to them
• Whether words like "rare" or "occasional" to describe side-effect frequency appear without numerical backing
• Whether diagrams or colors in patient-facing materials create an impression that exceeds the approved scope of efficacy
• Whether phrases like "across a broad range of patients" or "broadly applicable" obscure patient populations for whom the drug is actually contraindicated

Where (where these issues appear)  Patient brochures, patient medication guides (those issued under risk management plans), medication counseling aids, disease-awareness materials placed in waiting rooms, and visual aids used by physicians when explaining treatment to patients. Even materials originally designed for physicians are frequently used as-is when physicians explain a drug to a patient in the consultation room.

Why (why patients are particularly vulnerable)  Patients operate inside an information asymmetry. Physicians can read the approved package insert and ask a medical representative questions. A patient has only the material in hand and the explanation the physician provided. When anxious, a patient wants to believe the drug will work. Some patients do not have the mental space to read adverse-effect descriptions carefully. When a material's design — intentionally or not — exploits this vulnerability, the person harmed is the patient.

How (the regulatory framework for evaluation)  Article 68-2 of the Pharmaceuticals and Medical Devices Act obliges manufacturers and marketing authorization holders to provide appropriate information on adverse reactions and contraindications. The Fair Advertising Criteria for Pharmaceuticals prohibit exaggerated claims about efficacy in all advertising, including patient-facing materials, and require balance with safety information. The Guidelines on Sales Information Activities require that information be "accurate and based on facts regarding efficacy and safety" and that "negative information also be provided." Patient-facing material review is tested against all three layers simultaneously.

A Way In — Standing in That Position

Imagine a patient who has been prescribed a transdermal anti-inflammatory analgesic. In the clinic, the physician says, "This one works throughout the body." On the train home, the patient reads the brochure they were handed. There is a comparison diagram with oral medications and a topical-action patch. Their drug is shown in a deeper color, its effect range reaching to the body's extremities. The word "whole body" is larger than the surrounding text. The other drugs are shown in pale color, their effect ranges drawn narrower. The patient concludes: "Mine must be stronger." That interpretation may exceed the approved scope of efficacy, but the patient has no way to verify it.

Or consider a patient with reduced kidney function in a different situation. A physician receives a direct-mail piece about an antiviral drug and uses it on the spot to explain the drug to the patient. The piece states: "Consistent efficacy can be expected across patients with varied backgrounds." The physician prescribes without specific confirmation. But the drug is contraindicated in patients with an eGFR below 30. The electronic package insert says so; the direct mailer does not. The patient, trusting that a drug prescribed by a physician is safe, starts taking it.

Whether a reviewer can picture this scene as something that could happen to them. Whether they can sense that a single sentence in a material might lodge somewhere in this chain. That is what it means to hold the patient's eye. Not anger, not criticism — just the question "How would this person read this?" asked of oneself, material in hand, every time.

Past Cases as Mirrors — Rereading Violations Through This Eye

Case 1: Efficacy exaggerated through color and diagrams in a patient-facing material (FY2023, anti-inflammatory analgesic)

What happened  A patient-facing material for a systemic-action transdermal patch included a diagram that gave "the impression that the product's effects were stronger and more extensive" than those of oral medications and topical-action patches. The company's product was shown in a deep color with its effect range drawn out to the body's extremities. The word "whole body" was displayed larger than the surrounding text. An oral medication described in text as "acting throughout the body" was shown in pale color with a narrower effect range.

Reread through the patient's eye  A patient receiving this diagram is not in a position to choose between the compared drugs — the physician already chose. They simply want to know how well their drug works. The diagram's design aligns the patient's desire ("I want this to work well") with the company's interest ("I want this drug used continuously"). When the visual gives an impression beyond the approved efficacy, the patient has no means of checking. A diagram a reviewer might dismiss as something "physicians skim past" produces a decisive impression in the patient's hands.

Violation category  Recorded as a patient-facing material using exaggerated expression (FY2023 Monitoring Project Report). Conflicts with the intent of the Fair Advertising Criteria's prohibition on "superlative or equivalent expressions."

Case 2: A "works for any patient" sentence that omitted the contraindication (FY2024, antiviral agent)

What happened  A mass email distributed by medical representatives described an antiviral agent as "a drug for which consistent cure can be expected across patients with varied backgrounds." The electronic package insert listed patients with eGFR below 30 as a contraindication; that information was absent from the email. Additionally, the message omitted most of the company product's drug interactions while selectively listing interactions for a competing product, creating the false impression that the company's drug had fewer interactions and was easier to use. The monitoring report records that the content "gave the false impression that the company's product has few drug interactions and is easy to use, while the competing product has many interactions and is difficult to use."

Reread through the patient's eye  Physicians typically check the electronic package insert before prescribing. But direct mail is upstream of that step — it shapes the decision frame. When the phrase "consistent efficacy across a broad range of patients" pre-empts the physician's judgment, a patient who falls under the contraindication ends up on the receiving end. That patient assumes the physician knows about their eGFR. They assume that a drug that was prescribed is safe. Inside that chain of trust sits a missing line.

The full details of this violation are documented in Emphasis on Efficacy Alone / Minimizing Safety Information. The same series records safety-information imbalances across cases from FY2019 through FY2025.

keypoints